Free tool
FAERS Monitor: Aptiom
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022416 or its brand name (Aptiom, Eslicarbazepine Acetate). Reports on generic versions are filed under their own applications.
Reports
3,321
Serious
2,320
70% of reports
Hospitalization
712
Death reported
98
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- seizure1,014
- off label use324
- drug ineffective306
- dizziness231
- somnolence193
- hyponatraemia172
- fatigue158
- headache139
- generalised tonic-clonic seizure118
- fall117
- nausea106
- therapy interrupted100
- rash98
- product use in unapproved indication96
- feeling abnormal94
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 4 |
| 2013 | 4 |
| 2014 | 34 |
| 2015 | 123 |
| 2016 | 164 |
| 2017 | 247 |
| 2018 | 326 |
| 2019 | 397 |
| 2020 | 288 |
| 2021 | 397 |
| 2022 | 270 |
| 2023 | 266 |
| 2024 | 343 |
| 2025 | 267 |
| 2026 | 187 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,838 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| seizureSignal | 1,014 | 56.1 | 53.3 | 54,621 |
| generalised tonic-clonic seizureSignal | 118 | 45.5 | 38.1 | 5,056 |
| hyponatraemiaSignal | 172 | 19.4 | 16.8 | 2,982 |
| therapy interruptedSignal | 100 | 8.9 | 7.3 | 692 |
| somnolenceSignal | 193 | 6.1 | 5.3 | 820 |
| dizzinessSignal | 231 | 2.9 | 2.6 | 300 |
| feeling abnormalSignal | 94 | 2.5 | 2.0 | 83 |
| product use in unapproved indicationSignal | 96 | 2.5 | 2.0 | 82 |
| off label useSignal | 324 | 2.3 | 2.1 | 259 |
| fallSignal | 117 | 2.2 | 1.9 | 79 |
| drug ineffective | 306 | 1.5 | 1.3 | 49 |
| rash | 98 | 1.4 | 1.2 | 12 |
| headache | 139 | 1.4 | 1.2 | 16 |
| fatigue | 158 | 1.3 | 1.1 | 10 |
| nausea | 106 | 0.8 | 0.7 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.